Devyser acquires Swedish company Cybergene AB and strengthens its position in the aneuploidy market
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
This paper by Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital, Sweden, highlights the importance of chimerism as a diagnostic tool for clinicians treating transplanted patients. Furthermore, the evolution of novel diagnostic tools for early detection of mixed chimerism is discussed. The recent development of NGS technology offers the possibility to analyze mixed chimerism with both sensitivity, as well as accurate and precise determination.
This paper by Dr. Dan Hauzenberger, Medical Director of the Section for Transplantation Immunology at Karolinska University Hospital, Sweden, highlights the importance of chimerism as a diagnostic tool for clinicians treating transplanted patients. Furthermore, the evolution of novel diagnostic tools for early detection of mixed chimerism is discussed. The recent development of NGS technology offers the possibility to analyze mixed chimerism with both sensitivity, as well as accurate and precise determination.
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...
Read More